SHIRE PLC: Excellent Q3 upgrading 2006 revenue guidance (FinanzNachrichten)
Excellent third quarter with execution plan on track - upgrading 2006 revenue guidance Basingstoke, UK and Philadelphia, US - October 27, 2006 - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces results for the third quarter 2006.

Schering-Plough Announces FDA Approval Of NOXAFIL(R) (Posaconazole) For Treatment Of Oropharyngeal Candidiasis (OPC) (Medical News Today)
Schering-Plough Corporation (NYSE: SGP) today reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. [click link for full article]

Banking and Financial (Mondaq)
On September 19, 2006, the SEC s Office of the Chief Accountant (OCA) issued a letter that provides guidance regarding accounting for stock options in historical financial statements of public companies.